UroSCAN uses cookies to track visits to our website only, no personal information is collected.
By continuing to use the site you are agreeing to our use of cookies.
Understood
Quick and Selective
- the examination of the urine sample will last no longer than 10 min
- selective towards bladder cancer – our preliminary data suggest that the bladder cancer test specificity is as high as 80-90%
Low-Cost and Easy-to-Use
- one test will cost less than 4 EUR
- easy to use – the device is composed of a small spectrometer and exchangeable test tube, which works as a urine container simultaneously. Thanks to that, it is comfortable to use even at home by nonprofessionals
Digital
The results can be read, managed, and archived on mobile devices and computers, giving new opportunities for staying healthy
MEET UroSCAN
OUR STORY
Urine is one of the easiest biological materials for diagnostic. It has less complicated structure than blood, and it’s easier to characterize. The sample collection is easy and non-invasive manner. The samples have a high volume, so that their analysis gives the possibility to measure several parameters at once. They are characterized by high pepties and proteins stability in specimen and the obtained results reflect the physiological state of the body.
Read more
OUR VISION
The UroScan's strategy will be leading provider of fast and reliable diagnostic tests for various diseases basing on urine examination. There is an increasing number of scientific reports suggesting the presence of multiple biomarkers in the urine. Although, there is still a lack of methods to use widely in healthcare.
TECHNOLOGY
UroScan is a biotechnological start-up that is designed for conducting R&D and implementation of new solutions in the diagnostic area. The company aims to develop tools that will make diagnostic easier, faster, and more affordable. UroScan Company will introduce portable devices for general urine examination and non-invasive methods for bladder cancer detection. Still, in further perspective, the Company will launch dedicated tests for chronic kidney disease and ovarian cancer. In the long term, the company will provide research and development to detect various types of cancer in urine.
Team
Dawid Nidzworski
Co-Founder & CEO
